EXHIBIT 99.3

RESULTS ASSESSING ROLE OF EGFR EXPRESSION, AMPLIFICATION, AND MUTATION PUBLISHED
IN THE NEW ENGLAND JOURNAL OF MEDICINE

      MELVILLE, N.Y., Jul 13, 2005 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc.
(Nasdaq: OSIP) announced today that The New England Journal of Medicine (NEJM)
published results assessing the role of EGFR expression, amplification, and
mutation in a subset of patients from the pivotal Phase III study showing
Tarceva(R) (erlotinib) improved survival in patients with advanced non-small
cell lung cancer (NSCLC). The findings were reported in a companion paper
published with the clinical results of the BR.21 study in today's edition of the
NEJM. The U.S. Food and Drug Administration (FDA) approved Tarceva in November
2004 for the treatment of patients with locally advanced or metastatic NSCLC
after failure of at least one prior chemotherapy regimen.

      The results represent the first detailed assessment of the characteristics
of EGFR expression in a large, randomized, placebo-controlled, Phase III trial
and have provided additional insights into the role EGFR plays in NSCLC. The
authors concluded that the survival benefit from Tarceva therapy that was seen
for essentially all sub-sets of patients in the BR.21 study was greater,
although not significantly, for patients whose tumors expressed the EGFR protein
and for those patients whose tumors possessed an abnormally high copy number of
the EGFR gene. Interestingly, in the subset of patients analyzed, patients whose
tumors had mutations in their EGFR genes experienced no greater survival benefit
than patients whose tumors expressed the non-mutated - or "wild-type" - form of
the gene. The authors concluded that a mutation analysis is not necessary to
select patients in whom treatment with EGFR inhibitors is appropriate. Tarceva's
label does not limit prescribing to sub-set populations and it does not require
testing for EGFR expression or mutation prior to use.

      Molecular and Clinical Predictors of Response and Survival in Patients
Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials
Group Trial BR.21 - Ming-Sound Tsao, M.D. et al

      The publication reports an update of the analysis of EGFR protein
expression by immunohistochemistry (IHC) that was included in the U.S. Tarceva
package insert, and reports results of analyses of available tissue samples for
abnormal gene copy number, using a technique called fluorescence in-situ
hybridization (FISH), and for EGFR mutations. Analyses were carried out on
sub-sets of patient tumor samples that were available for each technique.

      Samples from 177 of the 731 patients in the study were successfully
analyzed for possible mutations in the EGFR gene. The results confirmed previous
observations that the tumor response rate was higher in the sub-set of patients
with mutations, however, when survival was assessed, there was no apparent
difference in survival benefit between those patients with wild-type or mutated
EGFR in their tumors (survival benefit was determined by comparing the overall
survival of patients receiving Tarceva with the overall survival of patients
receiving placebo for each patient group. The comparison results in a Hazard
Ratio (HR). A HR of less than one indicates a decrease in the risk of death. The
HR for patients whose tumors were determined to be "wild-type" was 0.73 (p=0.13)
and for patients whose tumors were "mutated" the HR was 0.77 (p=0.45)).



      Samples from 221 patients were available for FISH analysis of EGFR copy
number. Analysis of the data showed that patients found to have a high copy
number also had a more robust survival benefit (HR=0.44) than those with low
copy number (HR=0.85). Updated analyses including additional samples were
presented for EGFR protein expression measured by IHC. Forty-four percent
(325/731) of the patient tumor samples were available for analysis. Fifty-seven
percent of the patients were determined to be EGFR positive by IHC using the
criteria applied by the investigators and these patients had a significant
survival benefit (HR=0.68;p=0.02). A non-statistically significant HR of 0.93
was reported for the EGFR negative group.

ABOUT TARCEVA

      Tarceva is a small molecule designed to target the human epidermal growth
factor receptor 1 (HER1) pathway, which is one of the factors critical to cell
growth in non-small cell lung cancer (NSCLC) and other solid tumors. HER1, also
known as EGFR, is a component of the HER signaling pathway, which plays a role
in the formation and growth of numerous cancers. Tarceva is designed to inhibit
the tyrosine kinase activity of the HER1 signaling pathway inside the cell,
which may block tumor cell growth. Tarceva is the only HER1/EGFR-targeted
therapy proven to significantly prolong survival in second-line NSCLC.

      Tarceva was approved by the FDA in November 2004 and is an oral tablet
indicated for daily administration for the treatment of patients with locally
advanced or metastatic NSCLC after failure of at least one prior chemotherapy
regimen. Tarceva also received approval in Switzerland and Canada and received a
positive opinion from the European Committee for Medicinal Products for Human
Use (CHMP) recommending approval of Tarceva for the treatment of patients with
locally advanced or metastatic NSCLC.

      Results from two earlier large, randomized, placebo-controlled clinical
trials in first-line advanced NSCLC patients showed no clinical benefit with
concurrent administration of Tarceva with doublet platinum-based chemotherapy
(carboplatin and paclitaxel or gemcitabine and cisplatin) and its use is not
recommended in that setting.

TARCEVA SAFETY

      In the pivotal trial, the most common adverse reactions in patients
receiving Tarceva were rash and diarrhea. Grade 3/4 rash and diarrhea occurred
in nine and six percent of Tarceva-treated patients, respectively. Rash and
diarrhea each resulted in discontinuation of one percent of Tarceva-treated
patients. Six and one percent of patients needed dose reduction for rash and
diarrhea, respectively. In the Phase III trial, severe pulmonary reactions,
including potential cases of interstitial lung disease, were infrequent (less
than one percent) and were equally distributed between treatment arms.

ABOUT OSI PHARMACEUTICALS

      OSI Pharmaceuticals is committed to "shaping medicines and changing lives"
by discovering, developing and commercializing high-quality and novel
pharmaceutical products that extend life or improve the quality of life for
cancer and diabetes patients worldwide. The company operates through two
business teams, (OSI) Oncology and (OSI) Prosidion. (OSI) Oncology is focused on
developing molecular targeted therapies designed to change the



paradigm of cancer care. (OSI) Prosidion is committed to the generation of
novel, targeted therapies for the treatment of type 2 diabetes and obesity.
OSI's flagship product, Tarceva(R) (erlotinib), is the first drug discovered and
developed by OSI to obtain FDA approval and the only EGFR inhibitor to have
demonstrated the ability to improve survival in both non-small cell lung cancer
and pancreatic cancer patients. OSI markets Tarceva through partnerships with
Genentech, Inc. in the U.S. and with Roche throughout the rest of the world.

      In addition to Tarceva, (OSI) Oncology exclusively markets Novantrone(R)
(mitoxantrone concentrate for injection) for its approved oncology indications
and markets Gelclair(R) Bioadherent Oral Gel for the relief of pain associated
with oral mucositis. The research and development pipeline consists of novel
molecularly targeted anti-cancer agents focused on signal transduction pathways
involved in cell proliferation, apoptosis and angiogenesis. The most advanced of
these programs, targeting the co-inhibition of c-kit and VEGFR, has two
candidates in development.

      This news release contains forward-looking statements. These statements
are subject to known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the statements made.
Factors that might cause such a difference include, among others, the completion
of clinical trials, the FDA review process and other governmental regulation,
OSI's and its collaborators' abilities to successfully develop and commercialize
drug candidates, competition from other pharmaceutical companies, the ability to
effectively market products, and other factors described in OSI Pharmaceuticals'
filings with the Securities and Exchange Commission.

SOURCE: OSI Pharmaceuticals, Inc.
OSI Media and Investor Contact:
Kathy Galante, 631-962-2000